Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

Biogen's Q4 2024 earnings showed slight revenue ... The patent expiries of Tecfidera, Plegridy, and Tysabri have been chiefly responsible for the declines, and although Vumerity, approved in ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the shares following quarterly results. Though Biogen has ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 results. The company has successfully reprioritized R&D ...

Nguyen Thi Ngoc Diem, an Agent Orange victim in southern Vietnam.Credit...Linh Pham for The New York Times Supported by By Damien Cave Damien Cave reported from Dong Nai Province, where the U.S ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

This week’s Orange County high school baseball rankings. Notable this week: No. 1 Huntington Beach is playing its season opener this week. … JSerra has wins over Sierra Canyon and Notre Dame ...